Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Repligen (RGEN)

Repligen to acquire BioLife Solutions in $1.5 billion deal

Mixed Impact 5 of 5 m&a Written later

Repligen agreed to acquire BioLife Solutions for a total enterprise value of about $1.5 billion, paid in Repligen stock and cash, with closing expected in the fourth quarter of 2026. Repligen also reported preliminary second-quarter revenue growth of about 12% as reported and 13% organic, which it said is the company's own estimate and remains subject to its quarter-end close.

Key points

  • BioLife holders receive $11.25 cash plus 0.1442 Repligen shares per share, valued at $31.00 per share, a 24% premium to the 90-day VWAP ended July 21, 2026
  • Total enterprise value of about $1.5 billion, comprising 64% Repligen common stock and 36% cash; the cash is to come from cash on hand
  • Expected to close in the fourth quarter of 2026; BioLife may owe Repligen a $59,000,000 termination fee in certain circumstances
  • Preliminary Q2 2026 revenue growth of about 12% reported and 13% organic; Repligen will report full results on July 28, 2026

The filing

CompanyRepligen (RGEN)
Form8-K, current report
Filed with the SECJul 22, 2026, 8:56 AM ET
Accession number0001193125-26-311402

Items reported: 1.01 Material Definitive Agreement2.02 Results of Operations7.01 Regulation FD Disclosure8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 12:56 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 22, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.